When Supply Is of Public Interest: Roche & Tamiflu Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Roche 2005 revenue: CHF 35.5 billion (Exhibit 1).
Tamiflu 2005 revenue: CHF 1.6 billion (Exhibit 1).
Tamiflu production capacity: 2004 output was ~50 million treatment courses; planned 2006 capacity: 300 million courses (Paragraph 12).
Cost of pandemic preparedness: Roche invested CHF 100 million in manufacturing infrastructure without guaranteed purchase orders (Paragraph 15).

Operational Facts

Tamiflu is an antiviral drug for influenza; patents held by Gilead Sciences, licensed to Roche (Paragraph 3).
Manufacturing complexity: Oseltamivir phosphate synthesis involves a 10-step process requiring shikimic acid, a scarce precursor (Paragraph 11).
Supply chain: Gilead maintained control of the patent; Roche handled global manufacturing and distribution (Paragraph 4).

Stakeholder Positions

Roche: Focus on intellectual property protection, manufacturing scalability, and balancing public health with private profit.
Gilead: Patent holder seeking royalty payments (typically 10-15%).
Governments: Demanding generic licensing to ensure supply security during avian flu (H5N1) threats (Paragraph 18).
WHO: Pressing for increased global access and stockpiling (Paragraph 19).

Information Gaps

Specific terms of the Roche-Gilead licensing agreement regarding pandemic declarations.
Exact internal cost-per-course of production versus market pricing.
Regulatory hurdles for third-party manufacturers regarding quality control of the complex synthesis process.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should Roche manage the Tamiflu supply crisis to maximize long-term reputation and market stability while defending its core intellectual property rights against compulsory licensing threats?

Structural Analysis

Bargaining Power of Buyers: Governments act as monopsony buyers for pandemic stockpiling, possessing the power to invoke compulsory licensing if supply is deemed insufficient.
Threat of Substitutes: High. Other antivirals (e.g., Relenza) and potential vaccines reduce Tamiflu's unique status.
Threat of New Entrants: Patent laws protect the drug, but the threat of legislative overrides (compulsory licensing) effectively lowers entry barriers for generic producers.

Strategic Options

Option 1: Maintain Exclusive Control. Aggressively scale internal capacity. Trade-offs: High capital risk, potential for political backlash, risk of compulsory licensing if demand spikes.
Option 2: Voluntary Licensing. Partner with vetted generic manufacturers in key regions. Trade-offs: Dilutes IP control, creates potential quality control issues, reduces long-term margins.
Option 3: Public-Private Partnership. Work with WHO to manage distribution and pricing while keeping production centralized. Trade-offs: High operational complexity, aligns with global health goals, avoids IP loss.

Preliminary Recommendation

Pursue Option 3. Centralized production ensures quality and safety, while collaboration with the WHO mitigates the political risk of compulsory licensing. It positions Roche as a responsible global actor.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-2: Establish a Pandemic Task Force to coordinate with WHO and national health ministries.
Month 2-4: Finalize supply contracts with governments to secure demand volume; this justifies the capacity expansion cost.
Month 4-12: Execute the 300-million course production ramp-up.

Key Constraints

Shikimic Acid Scarcity: The primary bottleneck. Procurement must be prioritized over cost.
Regulatory Compliance: Maintaining FDA/EMA standards across a massive production scale-up is a significant operational burden.

Risk-Adjusted Implementation

Build contingency for supply chain disruptions by diversifying shikimic acid sourcing. If internal capacity fails to meet government targets by Month 6, initiate a controlled, limited-scope voluntary licensing agreement to preempt state-led compulsory licensing.

4. Executive Review and BLUF (Executive Critic)

BLUF

Roche must abandon the pursuit of absolute IP exclusivity for Tamiflu. The strategic threat is not market competition; it is the legislative seizure of intellectual property through compulsory licensing. By controlling the narrative and the production process via a public-private partnership with the WHO, Roche preserves its long-term patent integrity. Protecting the patent is secondary to protecting the company's license to operate. If Roche does not voluntarily expand supply through managed partnerships, governments will force the issue, resulting in total loss of control and reputation damage.

Dangerous Assumption

The analysis assumes that governments will prioritize Roche’s patent rights over population survival during a pandemic. This is a false premise; public health crises historically trigger the suspension of property rights.

Unaddressed Risks

Quality Failure: If a third-party partner produces sub-standard product, Roche bears the brand damage.
Pricing Backlash: High profit margins during a health crisis will invite permanent regulatory scrutiny and price caps.

Unconsidered Alternative

Tiered pricing and open-source manufacturing for developing nations only. This preserves premium pricing in developed markets while neutralizing the moral argument for compulsory licensing in the global south.